Top Banner
Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins Chapter 39 Antibiotics Affecting the Bacterial Cell Wall
34

Ppt chapter 39

Dec 04, 2014

Download

Documents

stanbridge

 
Welcome message from author
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Page 1: Ppt chapter 39

Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins

Chapter 39

Antibiotics Affecting the Bacterial Cell Wall

Chapter 39

Antibiotics Affecting the Bacterial Cell Wall

Page 2: Ppt chapter 39

Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins

Physiology Physiology

• Bacteria are surrounded by a rigid cell wall that is responsible for maintaining the integrity of the internal cellular environment.

• The interior of the cell has a high osmotic pressure.

• If the bacterial cell wall is not intact, the internal osmotic pressure draws fluid into the cell until it bursts.

• Even when the cell wall is breached by an antibiotic, bacterial death may not occur because of bacterial resistance.

Page 3: Ppt chapter 39

Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins

Physiology (cont.)Physiology (cont.)

• Drugs that affect the bacterial cell wall must be able to penetrate the cell wall to bind to molecular targets on the cell.

• Beta-lactamases are enzymes that disrupt the beta-lactam ring.

• This mechanism inactivates beta-lactam drugs.

Page 4: Ppt chapter 39

Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins

Cytoplasmic MembraneCytoplasmic Membrane

Page 5: Ppt chapter 39

Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins

Pathophysiology Pathophysiology

• Bacteria may cause infections in any body organ, structure, or fluid.

• In addition to the original bacterial infection, the loss of certain “good” bacteria may result in a superinfection.

Page 6: Ppt chapter 39

Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins

Penicillins Penicillins • Penicillins were the first antibiotics introduced for clinical

use.

• Alexander Fleming derived them from Penicillium molds in 1929.

• Subsequent versions of penicillin have been developed to decrease the adverse effects of the drug and to modify its ability to act on resistant bacteria.

• Penicillins are also called beta-lactam antibiotics because their chemical structure contains a beta-lactam ring that is essential for antibacterial activity.

• Penicillins are classified as narrow spectrum.

• Prototype drug: penicillin G

Page 7: Ppt chapter 39

Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins

Penicillin G: Core Drug Knowledge Penicillin G: Core Drug Knowledge

• Pharmacotherapeutics

– Infections caused by susceptible gram-positive bacteria

• Pharmacokinetics

– Administered: IM or IV. Highly protein bound. Excreted: kidneys.

• Pharmacodynamics

– Inhibits the third and final stage of bacterial cell wall synthesis

Page 8: Ppt chapter 39

Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins

Penicillin G: Core Drug Knowledge (cont.)Penicillin G: Core Drug Knowledge (cont.)

• Contraindications and precautions

– Known allergies to penicillin, cephalosporins, or imipenem

• Adverse effects

– GI upset, rash, fever, wheezing, possibly anaphylaxis and death

• Drug interactions

– Tetracyclines, aminoglycosides, and probenecid

Page 9: Ppt chapter 39

Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins

Penicillin G: Core Patient Variables Penicillin G: Core Patient Variables

• Health status

– Assess health history and allergies.

• Life span and gender

– The drug counteracts the effects of an oral contraceptive.

• Lifestyle, diet, and habits

– Administer the drug around the clock.

• Environment

– Assess the environment where the drug will be given.

Page 10: Ppt chapter 39

Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins

Penicillin G: Nursing Diagnoses and Outcomes Penicillin G: Nursing Diagnoses and Outcomes • Risk for Injury related to drug-related allergic reactions

– Desired outcome: The patient will recognize symptoms of allergy and contact the prescriber immediately to minimize ill effects.

• Imbalanced Nutrition: Less than Body Requirements related to drug-induced GI effects, such as diarrhea, GI upset, altered taste sensation, or superinfection

– Desired outcome: The patient will maintain consistent body weight and consult the prescriber about persistent adverse effects that affect nutritional status.

Page 11: Ppt chapter 39

Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins

Penicillin G: Nursing Diagnoses and Outcomes (cont.)Penicillin G: Nursing Diagnoses and Outcomes (cont.)

• Diarrhea related to drug therapy

– Desired outcome: The patient will avoid dehydration, maintain fluid intake, and contact the prescriber about persistent diarrhea.

• Risk for Infection related to overgrowth of nonsusceptible organisms

– Desired outcome: The patient will report signs of superinfection to the prescriber.

Page 12: Ppt chapter 39

Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins

Penicillin G: Planning and InterventionsPenicillin G: Planning and Interventions

• Maximizing therapeutic effects

– Review culture and sensitivity reports to make sure that penicillin G is appropriate for the patient.

– Optimally, drug therapy should continue for at least 7 to 10 days.

• Minimizing adverse effects

– Provide small, frequent meals; mouth care; and ice chips.

– Notify the prescriber if a substantial change develops in the intake-to-output ratio.

Page 13: Ppt chapter 39

Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins

Penicillin G: Teaching, Assessment, and EvaluationsPenicillin G: Teaching, Assessment, and Evaluations

• Patient and family education

– Stress the importance of completing the full course of antibiotics.

– Emphasize the need to take penicillin G exactly as prescribed at evenly spaced intervals.

• Ongoing assessment and evaluation

– Monitor for signs of allergic reaction and for resolution of the presenting symptoms of infection.

Page 14: Ppt chapter 39

Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins

QuestionQuestion

• Penicillin G is given via which of the following route(s)?

– A. Oral

– B. IM

– C. IV

– D. Both B and C

– E. All of the above

Page 15: Ppt chapter 39

Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins

AnswerAnswer

• D. Both B and C

• Rationale: Penicillin G is absorbed rapidly from the gastrointestinal (GI) tract but is unstable in gastric acid. Because of this instability, penicillin G is not given orally.

Page 16: Ppt chapter 39

Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins

Cephalosporins Cephalosporins • The cephalosporins were first introduced in the 1960s.

• They are similar to the penicillins in structure and in activity and are also considered beta-lactam antibiotics.

• Four generations of cephalosporins have been introduced, each group with its own spectrum of activity.

• Selecting an antibiotic from this class depends on the sensitivity of the involved organism.

• The major differences between the generations include their activity against gram-negative bacteria, their resistance to beta-lactamases, and their ability to distribute into cerebrospinal fluid.

• Prototype drug: cefazolin (Ancef, Kefzol)

Page 17: Ppt chapter 39

Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins

Cefazolin: Core Drug Knowledge Cefazolin: Core Drug Knowledge

• Pharmacotherapeutics

– Treats many kinds of infections

• Pharmacokinetics

– Administered: IM. Peak: 1.5 to 2 hours.

• Pharmacodynamics

– Binds with PBPs, which disrupts bacterial cell wall synthesis

Page 18: Ppt chapter 39

Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins

Cefazolin: Core Drug Knowledge (cont.)Cefazolin: Core Drug Knowledge (cont.)

• Contraindications and precautions

– Known allergy to cephalosporins

• Adverse effects

– Maculopapular rash, GI symptoms, headache, dizziness, lethargy, paresthesias, and nephrotoxicity

• Drug interactions

– Aminoglycosides

Page 19: Ppt chapter 39

Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins

Cefazolin: Core Patient Variables Cefazolin: Core Patient Variables

• Health status

– Assess history and allergies.

• Life span and gender

– Assess for pregnancy and lactation.

• Lifestyle, diet, and habits

– Assess lifestyle to ensure ability to comply with therapy.

• Environment

– Assess the environment where the drug will be given.

Page 20: Ppt chapter 39

Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins

Cefazolin: Nursing Diagnoses and Outcomes Cefazolin: Nursing Diagnoses and Outcomes

• Diarrhea related to drug effects

– Desired outcome: The patient will avoid dehydration, maintain fluid intake, and contact the prescriber if diarrhea persists.

• Imbalanced Nutrition: More or Less than Body Requirements related to GI effects, alteration in taste, superinfections

– Desired outcome: The patient will maintain body weight and contact the prescriber if persistent adverse effects alter nutritional status.

• Risk for Infection related to overgrowth of nonsusceptible organisms

– Desired outcome: The patient will report signs of superinfection to the prescriber.

Page 21: Ppt chapter 39

Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins

Cefazolin: Planning and InterventionsCefazolin: Planning and Interventions

• Maximizing therapeutic effects

– Review culture and sensitivity tests to evaluate the efficacy of treatment.

– Oral suspensions should be kept in the refrigerator.

• Minimizing adverse effects

– Cefazolin may be taken with food or fluids to decrease GI distress.

– Evaluate the patient for CNS effects and use safety precautions.

Page 22: Ppt chapter 39

Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins

Cefazolin: Teaching, Assessment, and EvaluationsCefazolin: Teaching, Assessment, and Evaluations

• Patient and family education

– Because cefazolin and the other cephalosporins are similar to penicillins, follow the same guidelines for providing patient and family education to a patient receiving penicillin.

• Ongoing assessment and evaluation

– Monitor the patient for any signs of superinfection and notify the prescriber immediately to arrange for treatment if superinfection does occur.

Page 23: Ppt chapter 39

Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins

QuestionQuestion

• First-generation cephalosporins are effective at treating gram-negative infections.

– A. True

– B. False

Page 24: Ppt chapter 39

Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins

AnswerAnswer

• B. False

• Rationale: The first-generation cephalosporins have little activity against gram-negative bacteria.

Page 25: Ppt chapter 39

Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins

Vancomycin Vancomycin

• Vancomycin (Vancocin) is a complex and unusual tricyclic glycopeptide antibiotic.

• It is the only drug in its class.

• The use of vancomycin is limited by its ability to produce toxic effects.

• Vancomycin is used only when other antibiotics fail to resolve an infection.

• It has been touted as being able to eradicate most gram-positive pathogens.

Page 26: Ppt chapter 39

Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins

Vancomycin: Core Drug Knowledge Vancomycin: Core Drug Knowledge

• Pharmacotherapeutics

– Treating bacterial septicemia, endocarditis, bone and joint infections

• Pharmacokinetics

– Administered: oral or IV. Excreted: kidneys and feces. Peak: 1 hour.

• Pharmacodynamics

– Inhibits cell wall synthesis by altering the cell’s permeability

Page 27: Ppt chapter 39

Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins

Vancomycin: Core Drug Knowledge (cont.)Vancomycin: Core Drug Knowledge (cont.)

• Contraindications and precautions

– Hypersensitivity and pregnancy

• Adverse effects

– Ototoxicity and nephrotoxicity

• Drug interactions

– Antihyperlipidemic drugs and nondepolarizing muscle relaxants

Page 28: Ppt chapter 39

Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins

Vancomycin: Core Patient Variables Vancomycin: Core Patient Variables

• Health status

– Assess for contraindications to therapy.

• Life span and gender

– Assess pregnancy and lactation status.

• Environment

– Assess the environment where the drug will be given.

Page 29: Ppt chapter 39

Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins

Vancomycin: Nursing Diagnoses and Outcomes Vancomycin: Nursing Diagnoses and Outcomes

• Risk for Injury related to drug-induced histamine-release reactions

– Desired outcome: The patient will experience no preventable reaction related to vancomycin.

• Disturbed Sensory Perception (auditory) related to drug-induced ototoxicity

– Desired outcome: The patient will report any unusual auditory sensations and have periodic audiograms to detect early ototoxicity.

Page 30: Ppt chapter 39

Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins

Vancomycin: Nursing Diagnoses and Outcomes (cont.)Vancomycin: Nursing Diagnoses and Outcomes (cont.)

• Excess Fluid Volume related to nephrotoxicity from drug therapy

– Desired outcome: The patient will remain normovolemic throughout therapy.

• Risk for Infection related to overgrowth of nonsusceptible organisms

– Desired outcome: The patient will report signs of superinfection to the prescriber.

Page 31: Ppt chapter 39

Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins

Vancomycin: Planning and InterventionsVancomycin: Planning and Interventions

• Maximizing therapeutic effects

– Ensure that the patient receives the full course of vancomycin as prescribed.

– Culture and sensitivity results should be monitored.

• Minimizing adverse effects

– Administer vancomycin over at least 60 minutes.

– Assess the IV site frequently for signs of phlebitis.

Page 32: Ppt chapter 39

Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins

Vancomycin: Teaching, Assessment, and EvaluationsVancomycin: Teaching, Assessment, and Evaluations• Patient and family education

– Advise the patient of the importance of completing therapy.

– Explain the potential adverse effects and need for periodic blood monitoring.

• Ongoing assessment and evaluation

– Monitor for signs of ototoxicity.

– For patients receiving long-term or high-dose therapy, coordinate periodic audiometric testing and lab tests.

Page 33: Ppt chapter 39

Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins

QuestionQuestion

• The oral form of vancomycin is used to treat

– A. Gastric ulcers

– B. Prostatitis

– C. Rupture of diverticulum

– D. Pseudomembranous colitis

Page 34: Ppt chapter 39

Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins

AnswerAnswer

• D. Pseudomembranous colitis

• Rationale: Oral administration is used in treating some GI infections, such as pseudomembranous colitis.